112 completed, 26 unknown, 15 recruiting, 9 not yet recruiting. 44 Phase 4, 39 Phase 1, 32 Phase 3, 31 Phase 2, 13 Not applicable.
Follow mirabegron: new trials by email Literature Review of mirabegron trials Research Report on mirabegron
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder Mirabegron (beta3-adrenoceptor agonist) - Overactive Bladder (OAB) | Not yet recruiting | Bagcilar Training and Research Hospital | 115 | 2026-11-01 | 2026-10-05 | |
| Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity Alpha-lipoic acid, Mirabegron, Placebo - Insulin Resistance, Obesity | Phase 2 | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 60 | 2026-10-27 | 2026-10-22 |
| Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease mirabegron, Exercise-based behavioral therapy - Overactive Bladder, Parkinson Disease | Phase 4 | Not yet recruiting | VA Office of Research and Development | 146 | 2026-10-21 | 2026-10-19 |
| Burden and Efficacy of Anticholinergic vs Mirabegron in Overactive Bladder - A Randomized Controlled Study Solifencin, Mirabegron - Overactive Bladder (OAB) | Phase 4 | Not yet recruiting | Universidade do Porto | 208 | 2026-07-01 | 2026-07-17 |
| Using Mirabegron to Control Arrhythmia-1 Mirabegron - Ventricular Arrhythmias and Cardiac Arrest | Phase 2 | Not yet recruiting | Cedars-Sinai Medical Center | 20 | 2026-05-01 | 2026-05-06 |
| Beta-3 Enhanced Autonomic Therapy for POTS Mirabegron, Placebo - Postural Orthostatic Tachycardia Syndrome (POTS) | Phase 2 | Not yet recruiting | Cedars-Sinai Medical Center | 36 | 2026-05-01 | 2026-05-13 |
| Mirabegron in Patients With Age-Related Macular Degeneration Mirabegron 50mg, Solifenacin 5mg - Dry AMD, Overactive Bladder | Not yet recruiting | University of Naples | 312 | 2026-04-01 | 2026-02-06 | |
| Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion Mirabegron, Tamsulosin - Ureteral Calculi | Phase 4 | Recruiting | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | 500 | 2026-02-13 | 2026-10-01 |
| Effect of Antimuscarinic Treatment on Premature Ejaculation Severity in Men With Overactive Bladder: a Prospective Comparison With Mirabegron Tolterodine, Mirabegron (beta3-adrenoceptor agonist) - Overactive Bladder (OAB), Premature (Early) Ejaculation | Completed | Başakşehir Çam & Sakura City Hospital | 40 | 2026-01-15 | 2026-08-13 | |
| Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron - Ovarian Cancer, Immunotherapy | Phase 2 | Recruiting | Obstetrics & Gynecology Hospital of Fudan University | 20 | 2025-12-01 | 2025-12-19 |
| Behavioral Interventions Versus Pelvic Floor Muscle Therapy as Adjuncts to Anticholinergic Pharmacotherapy for Urgency Urinary Incontinence: A Non-Inferiority Trial Pelvic Floor Muscle Training (PFMT), Behavioral Bladder Training Program, Oxybutynin / Mirabegron (Standardized Pharmacotherapy) - Urgency Urinary Incontinence | Not applicable | Active not recruiting | Emilio José Dávila Álvarez | 80 | 2025-11-22 | 2026-01-26 |
| Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms Tamsulosin Hydrochloride 0.4 mg, Solifenacin Succinate 5 mg, Mirabegron 25 mg - Ureteral Stent-Related Symptom | Phase 3 | Recruiting | Bir Hospital | 189 | 2025-08-30 | 2025-09-08 |
| The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial Mirabegron 25mg, Solifenacin 5 mg, Tolterodine 4 mg - Urinary Bladder, Overactive | Phase 3 | Not yet recruiting | Far Eastern Memorial Hospital | 220 | 2025-08-07 | 2025-08-11 |
| Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period Beta-3 agonists (Mirabegron/Myrbetriq), Placebo group post rezum - Benign Prostate Hypertrophy(BPH) | Phase 3 | Not yet recruiting | University of Manitoba | 50 | 2025-08-01 | 2025-06-12 |
| Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes Urodynamic evaluation before and after solifenacin treatment., Urodynamic evaluation before and after mirabegron treatment., Urodynamic evaluation before and after combined treatment with solifenacin and mirabegron. - Overactive Bladder (OAB) | Not applicable | Recruiting | Mackay Medical College | 60 | 2025-07-01 | 2025-06-17 |
| Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer Pegylated liposomal doxorubicin plus adebrelimab with mirabegron, Pegylated liposomal doxorubicin plus adebrelimab - Ovarian Cancer Recurrent | Phase 2 / Phase 3 | Recruiting | Obstetrics & Gynecology Hospital of Fudan University | 296 | 2025-03-18 | 2025-03-18 |
| Efficacy and Safety of Mirabegron Versus Oxybutynin After Posterior Urethral Valve Ablation Mirabegron - Posterior Urethral Valve | Not applicable | Completed | South Valley University | 52 | 2025-01-01 | 2026-06-29 |
| Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE Mirabegron (beta3-adrenoceptor agonist), Anticholinergics, Desmopressin (DDAVP) - Nocturnal Enuresis in Children | Phase 3 | Recruiting | Mansoura University | 120 | 2024-12-01 | 2025-09-30 |
| Evaluation of Mirabegron Versus Tamsulosin or Their Combination in Treatment of Lower Urinary Tract Symptoms Tamsulosin - Ureteric Stent-related Morbidity | Not applicable | Completed | Avraiem Talaat | 300 | 2024-10-10 | 2025-12-29 |
| Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study Mirabegron - NSCLC, SCLC | Phase 2 | Recruiting | Zhejiang Provincial People's Hospital | 260 | 2024-07-15 | 2024-08-02 |
Showing 20 of 176. Sign in to see all of them.
Urinary Bladder, Overactive (78) · Urinary Incontinence (23) · Urinary Incontinence, Urge (11) · Lower Urinary Tract Symptoms (8) · Nocturia (7) · Obesity (7) · Prostatic Hyperplasia (6) · Urinary Bladder Diseases (5) · Urologic Diseases (5) · Parkinson Disease (4) · Spinal Cord Injuries (4) · Diabetes Mellitus, Type 2 (3) · Ureterolithiasis (3) · Urinary Bladder, Neurogenic (3) · Cystitis, Interstitial (2)
Astellas Pharma Inc (36) · Astellas Pharma Europe B.V. (13) · Astellas Pharma Global Development, Inc. (5) · Far Eastern Memorial Hospital (5) · Mansoura University (4) · Astellas Pharma China, Inc. (3) · Astellas Pharma Europe Ltd. (3) · Buddhist Tzu Chi General Hospital (3) · Cedars-Sinai Medical Center (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Philip Kern (3) · Seoul National University Hospital (3) · University of California, San Francisco (3) · Astellas Pharma Singapore Pte. Ltd. (2) · CHU de Quebec-Universite Laval (2)
United States (56) · Taiwan (21) · Canada (19) · Denmark (16) · France (16) · South Korea (15) · Germany (14) · Egypt (13) · Japan (13) · Poland (13) · United Kingdom (13) · Belgium (12) · Netherlands (12) · Czechia (11) · Norway (11)
Aaron M Cypess, M.D. (2) · Ahmed Elshafeey, Ph.D. Pharma (2) · Blair D Johnson, PhD (2) · Hann-Chorng Kuo, M.D. (2) · Hui-Hsuan Lau, MD (2) · Luise Borch, MD, PhD (2) · Philip Kern, MD (2)
PMID 37160401, PMID 24246044, PMID 23769122, PMID 25565203, PMID 26876327, PMID 10027879, PMID 10188996, PMID 10797303, PMID 11176525, PMID 11412210, PMID 11857671, PMID 12007519, PMID 12579626, PMID 12579627, PMID 12811491, PMID 14693111, PMID 14973214, PMID 16406907, PMID 16753445, PMID 16813910, PMID 17010004, PMID 17574730, PMID 18311486, PMID 18423678, PMID 18565239, PMID 19089891, PMID 19220267, PMID 19254402, PMID 19281469, PMID 19302497, PMID 1939656, PMID 19816919, PMID 19889062, PMID 19941278, PMID 20132203, PMID 21371240, PMID 21501328, PMID 22258963, PMID 22310924, PMID 22362256, PMID 22531957, PMID 22588142, PMID 22981677, PMID 23424164, PMID 23452071, PMID 23586728, PMID 23727415, PMID 24612659, PMID 25022469, PMID 25086164
2008 (7), 2015 (3), 2016 (2), 2004 (1), 2014 (1), 2023 (1), I01RD000466 (1), K24AG068601 (1), P30DK036836 (1), R01AG075471 (1), R01AG076575 (1), R01DK112282 (1), R01DK124626 (1), R01DK128033 (1), R21AG081900 (1)